Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- cerebrovascular disorders
- cholesterol (LDL)
- coronary disease
- drug delivery systems
- heptanoic acids
Q In patients with stable coronary heart disease (CHD), is intensive atorvastatin therapy more effective than moderate atorvastatin therapy for reducing cerebrovascular events?
Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Neurology ★★★★★★☆ Endocrine ★★★★★★☆
randomised controlled trial.
blinded (clinicians, patients, and endpoints adjudication committee).*
Follow up period:
median 4.9 years.
256 sites in 14 countries across 4 continents.
10 001 patients 35–75 years of age (mean age 61 y, 81% men) who had clinically evident CHD (defined as previous myocardial infarction or coronary revascularisation, or previous or current angina with objective evidence of CHD), low density lipoprotein cholesterol (LDL-C) concentration 130–250mg/dl (3.4–6.5 mmol/l), and triglyceride concentration ⩽600 mg/dl (6.8 mmol/l). LDL-C concentration was required to be <130 mg/dl (3.4 mmol/l) during an 8 week run in period with atorvastatin, 10 mg/day.
atorvastatin, 80 mg/day (n = 4995) …